摘要
目的观察了解雌激素受体（ER）和（或）孕激素受体（PR）阳性乳腺癌（Luminal型）首发肝转移患者的临床特征及预后。方法收集2000年1月至2011年12月中国医学科学院肿瘤医院收治的182例首发肝转移的Luminal型乳腺癌患者的临床资料，回顾性分析其临床特点，探讨其治疗及预后相关情况。结果全组患者中位年龄为47岁（23～73岁），〈50岁患者118例（64．8％）；全部患者一线治疗均采用化疗，有效率（完全缓解3例＋部分缓解107例）为60．4％。患者术后中位无病生存期（DFS）为19．5个月，肝转移后中位无进展生存期（PFS）为8个月，总生存期为23个月。肝转移时年龄≤50岁较〉50岁的患者总生存期延长7个月，两组间差异有统计学意义（P〈0．05）；一线治疗达完全缓解或部分缓解患者较疗效为疾病稳定或疾病进展患者在PFS及总生存期分别显著延长3个月和7个月（P〈0．05）。含卡培他滨化疗方案对于PFS及总生存期方面的影响差异均无统计学意义（均P〉0．05）。结论对于ER和（或）PR阳性的Luminal型乳腺癌首发肝转移患者，年龄以及初次化疗的疗效为影响生存的独立预后因素。
Objective To explore the clinical characteristics and prognosis of estrogen receptor/ progesterone receptor （ER/PR） positive breast cancer （luminal subtype ） patients with liver metastases. Methods A total of 182 patients with liver metastasis from luminal subtype breast cancer between January 2000 and December 2011 were retrospectively reviewed. Their clinical characteristics, treatments and prognosis were collected and analyzed. Results Their median age was 47 years and 118 patients were younger than 50 years old. The median disease-free survival （DFS） after primary operation of breast cancer was 19. 5 months. All patients received first-line chemotherapy for liver metastases. Overall response （ CR ＋ PR） rate was 60. 4% （ 110/182 ）. Progression-free survival （PFS） and overall survival （OS） were 8 and 23 months respectively. The median OS was extended by 7 months in younger patients （≤50） than in older ones （〉50） （P 〈0. 05）. In addition, PFS and OS were also extended by 3 and 7 months in patients with complete and partial responses than those who had stable and progressive diseases （P 〈 0. 05）. No difference existed in PFS and OS with or without capecitabine-based regimens （ both P 〉 0. 05）. Conclusion Age and response to treatment are independent prognostic factors for ER and/or PR positive breast cancer patients with liver metastasis.
出处
《中华医学杂志》
CAS
CSCD
北大核心
2014年第4期260-264,共5页
National Medical Journal of China
关键词
乳腺肿瘤
肿瘤转移
预后
肝转移
Breast neoplasms
Neoplasm metastasis
Prognosis
Liver metastasis
